JAZZ Stock Analysis: Buy, Sell, or Hold?
JAZZ - Jazz Pharmaceuticals, Inc.
$164.49
0.51 (0.31%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 24, 2026
24d
Get Alerted When JAZZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: JAZZ shows positive signals but monitor for confirmation. Market pricing in 0.5% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: JAZZ shows positive signals but monitor for confirmation. Market pricing in 0.5% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$312.70
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$194.16
15.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JAZZ is currently trading at $164.49, which is considered oversold relative to its 30-day fair value range of $164.62 to $171.65. The stock's valuation (Forward PE: 7.7) is in line with its historical norms (7.5). At these levels, the market is pricing in 0.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, JAZZ is in a strong uptrend. The price is currently testing key support at $162.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: JAZZ has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $216.44 (+32.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JAZZ is in a strong uptrend. The price is currently testing key support at $162.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: JAZZ has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $216.44 (+32.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$164.62 -
$171.65
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.0% below Wall St target ($216.44)
- NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$164.62 -
$171.65
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$5.98
(3.6%)
Support & Resistance Levels
Support Level
$162.68
Resistance Level
$172.59
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
7.66
Wall Street Target
$216.44
(+32.0%)
Revenue Growth (YoY)
6.7%
Earnings Growth (YoY)
19.3%
Profit Margin
-8.9%
Valuation Premium vs History
+0.5% premium
PE vs Historical
7.7 vs 7.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.5%
(market-implied from PE analysis)
1-Year Target
$164.80
(+1%)
2-Year Target
$165.62
(+1%)
3-Year Target
$166.45
(+2%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
PE COMPRESSION
$163.00
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 164.5%)
$1611.38
(+883%)
Base:
(SPY PE: 7.7, Growth: 164.5%)
$553.43
(+238%)
Bear:
(PE: 6.5, Growth: 164.5%)
$470.42
(+187%)
Last updated: January 30, 2026 5:40 PM ET
Data refreshes hourly during market hours. Next update: 6:40 PM
Data refreshes hourly during market hours. Next update: 6:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAZZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Bruce C Cozadd
SELL
3500 shares
2025-10-03
Bruce C Cozadd
SELL
2000 shares
2025-10-01
Bruce C Cozadd
SELL
6000 shares
2025-09-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced JAZZ Option Strategies
Professional options setups generated by AI based on today's JAZZ price and gamma walls.
